서론
본론
1. 당뇨병환자에서의 이상지질혈증
1) 현황
2) 특징
이상지질혈증의 관리
1) 관리의 목표 및 배경
2) 평가
② CVD 위험 평가 및 조절 목표 설정
Table 1.
KDA/KsoLA (2023) | ACC/AHA (2018) | ESC/EAS (2019) |
---|---|---|
DM duration < 10 years, without major risk factors: LDL-C < 100 mg/dL | DM without ASCVD or without multiple risk factors (moderate intensity statin) | DM with moderate risk (LDL-C < 100 mg/dL): young patients (T1DM < 35 years; T2DM < 50 years) with DM duration < 10 years, without other risk factors |
DM duration ≥ 10 years or DM with major risk factors, or with target organ damage a: LDL-C < 70 mg/dL • If, ≥ 3 major risk factors or with target organ damage: LDL-C < 55 mg/dL; optional |
Aged < 40 years with additional risk factors (moderate-intensity statin) All ages with 10-year atherosclerotic cardiovascular disease risk > 20% or multiple ASCVD risk factors (high intensity statin) |
DM with high risk (LDL-C < 70 mg/dL + 50% ↓): DM duration ≥ 10 years or another additional risk factor |
DM with ASCVD: LDL-C < 55 mg/dL + 50% ↓ |
DM with ASCVD: high-intensity statin therapy • If LDL-C is ≥ 70 mg/dL on the maximally tolerated statin dose, additional LDL-C lowering therapy recommended |
DM with very high risk (LDL-C < 55 mg/dL + 50% ↓)
|
KDA, Korean Diabetes Association; KsoLA, Korean Society of Lipid and Atherosclerosis; ACC/AHA, American College of Cardiology/American Heart Association; ESC/EAS, European Society of Cardiology/European Atherosclerosis Society; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
3) 치료
① 생활습관교정
② 약물치료
Fig. 1.
